A5068260242- Venous Thromboembolism Diagnosis and Management
- Atrial Fibrillation Management and Outcomes
- Blood Coagulation and Thrombosis Mechanisms
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- Erythropoietin and Anemia Treatment
- Hemoglobinopathies and Related Disorders
- Central Venous Catheters and Hemodialysis
- Iron Metabolism and Disorders
- Neutropenia and Cancer Infections
- Antiplatelet Therapy and Cardiovascular Diseases
- Hematological disorders and diagnostics
- COVID-19 and healthcare impacts
- Heparin-Induced Thrombocytopenia and Thrombosis
- Blood disorders and treatments
- COVID-19 Clinical Research Studies
- Lymphoma Diagnosis and Treatment
- Acute Ischemic Stroke Management
- Diagnosis and Treatment of Venous Diseases
- Cancer Treatment and Pharmacology
- Complement system in diseases
- Hematopoietic Stem Cell Transplantation
- Cardiac tumors and thrombi
- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
Western University
2015-2024
London Health Sciences Centre
2014-2024
King Abdulaziz University
2023
Matsushita Memorial Hospital
2022
Panasonic (Japan)
2022
Kyoto Prefectural University of Medicine
2022
Victoria Hospital
2008-2021
Institute for Clinical Evaluative Sciences
2014-2018
King Abdulaziz Medical City
2016
University of Ottawa
2005-2015
Retrospective analyses suggest that pulmonary embolism is ruled out by a d-dimer level of less than 1000 ng per milliliter in patients with low clinical pretest probability (C-PTP) and 500 moderate C-PTP. We performed prospective study which was considered to be without further testing outpatients C-PTP or milliliter. All other underwent chest imaging (usually computed tomographic angiography). If not diagnosed, did receive anticoagulant therapy. were followed for 3 months detect venous...
Venous thromboembolism may be the earliest sign of cancer. Currently, there is a great diversity in practices regarding screening for occult cancer person who has an unprovoked venous thromboembolism. We sought to assess efficacy strategy that included comprehensive computed tomography (CT) abdomen and pelvis patients had first thromboembolism.We conducted multicenter, open-label, randomized, controlled trial Canada. Patients were randomly assigned undergo limited occult-cancer (basic blood...
Oral factor Xa inhibitors are increasingly used for anticoagulation, but there is no approved reversal agent. Prothrombin complex concentrate (PCC) the management of Xa-inhibitor-associated bleeding has been described in small case series and one cohort study. Patients on apixaban or rivaroxaban, suffering a major bleed, were treated at nine Canadian hospitals as per existing hospital protocol with fixed dose PCC 2,000 units subsequently recruited 30-day follow-up. The treating physician...
Background— Long-term low-molecular-weight heparin (LMWH) is the current standard for treatment of venous thromboembolism (VTE) in cancer patients. Whether strategies should vary according to individual risk VTE recurrence remains unknown. We performed a retrospective cohort study and validation patients with cancer-associated derive clinical prediction rule that stratifies risk. Methods Results— The 543 determined model best classification performance included 4 independent predictors (sex,...
To update the American Society of Clinical Oncology (ASCO)/American Hematology (ASH) recommendations for use erythropoiesis-stimulating agents (ESAs) in patients with cancer.PubMed and Cochrane Library were searched randomized controlled trials (RCTs) meta-analyses RCTs cancer published from January 31, 2010, through May 14, 2018. For biosimilar ESAs, literature search was expanded to include or chronic kidney disease cohort studies due limited RCT evidence setting. ASCO ASH convened an...
Abstract Objective To determine the efficacy and safety of dalteparin postoperative bridging treatment versus placebo for patients with atrial fibrillation or mechanical heart valves when warfarin is temporarily interrupted a planned procedure. Design Prospective, double blind, randomised controlled trial. Setting 10 thrombosis research sites in Canada India between February 2007 March 2016. Participants 1471 aged 18 years older who required temporary interruption Intervention Random...
Abstract Heparins and vitamin K antagonists are the mainstay of treatment splanchnic vein thrombosis (SVT). Rivaroxaban is a potential alternative, but data to support its use limited. We aimed evaluate safety efficacy rivaroxaban for acute SVT. In an international, single-arm clinical trial, adult patients with first episode noncirrhotic, symptomatic, objectively diagnosed SVT received 15 mg twice daily 3 weeks, followed by 20 intended duration months. Patients Budd-Chiari syndrome those...
Background The field of oncology is at the forefront advances in artificial intelligence (AI) health care, providing an opportunity to examine early integration these technologies clinical research and patient care. Hope that AI will revolutionize care delivery improve outcomes has been accompanied by concerns about impact on equity. Objective We aimed conduct a scoping review literature address question, “What are current potential impacts equity oncology?” Methods Following PRISMA-ScR...
Background . Thrombocytosis is a common reason for referral to Hematology. Differentiating between secondary causes of thrombocytosis and essential thrombocythemia (ET) often clinically challenging. A practical diagnostic approach identify could reduce overinvestigation such as next generation sequencing (NGS) panel. Methods Results All adult patients with (≥450 × 10 9 /L) who underwent molecular testing at single tertiary care centre January 1, 2018 May 31, 2021 were evaluated. Clinical...
Background: The incidence of pulmonary embolism has been increasing, but its case-fatality rate is decreasing, suggesting a lesser severity illness. clinical importance patients with isolated to the subsegmental vessels unknown. Objective: To determine recurrent venous thromboembolism in managed without anticoagulation. Design: Multicenter prospective cohort study. (ClinicalTrials.gov: NCT01455818) Setting: Eighteen sites between February 2011 and 2021. Patients: Patients embolism....
Variable warfarin response during treatment initiation poses a significant challenge to providing optimal anticoagulation therapy. We investigated the determinants of initial in cohort 167 patients. During first nine days with pharmacogenetics-guided dosing, S-warfarin plasma levels and international normalized ratio were obtained serve as inputs pharmacokinetic-pharmacodynamic (PK-PD) model. Individual PK (S-warfarin clearance) PD (Imax) parameter values estimated. Regression analysis...